Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has provided an announcement.
MindBio Therapeutics has appointed Chilean drug and alcohol policy expert and mining safety authority Felipe Leyton to lead commercialization of its voice-initiated AI drug and alcohol screening platform in the South American mining sector. Leyton’s background in designing and implementing Chile’s Zero Tolerance alcohol law and national roadside drug testing, coupled with his advisory work for major mining operators, is expected to accelerate enterprise adoption and revenue generation in one of the world’s highest-risk industrial markets.
Under his mandate, Leyton will help finalize mining-specific testing protocols, extend clinical validation, and strengthen the platform’s multi-substance detection capabilities while creating scalable licensing frameworks for mining companies. MindBio is nearing completion of its Edge AI kiosk system, with on-site field testing at mining operations slated for Q2 2026, addressing a large and urgent safety market where substance use is a major contributor to industrial accidents and positioning the company at the forefront of next-generation industrial safety technologies.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a biotechnology company developing AI-powered voice analytics to deliver real-time drug and alcohol impairment detection. The company is building integrated Edge AI hardware-software kiosks for industrial environments, targeting safety-critical sectors such as the global mining industry with scalable, non-invasive screening solutions.
Average Trading Volume: 9,082
Technical Sentiment Signal: Sell
Current Market Cap: C$1.74M
For detailed information about MBIO stock, go to TipRanks’ Stock Analysis page.